What happened Core Laboratories (NYSE: CLB) published its latest set of quarterly results after market hours on Wednesday, revealing slight misses on both the top and bottom lines. Investors clearly weren't in an understanding or forgiving mood the following day, and they traded the specialty oilfield services company's stock down by 1% on an otherwise up day for the broader market. So what For its second quarter, Core Labs lifted its revenue nearly 5% higher on a year-over-year basis to just shy of $121 million. On the bottom line, the company flipped to a GAAP profit of slightly over $7 million, or $0.15 per share. On a non-GAAP (adjusted) basis, that per-share net income figure was $0.12. That wasn't quite enough to meet the average consensus analyst estimate of $0.14 per share. Nor was revenue, which those prognosticators were collectively modeling at slightly under $122 million. Core Labs, which operates around the world, said that the strong U.S. dollar negatively affected its financials, as did the war in Ukraine. Now what Nevertheless, sounding an upbeat note, Core Labs said it's forecasting "improving momentum in both onshore and offshore client activity across our global operations." Reflecting this optimistic tone, the company is guiding for third-quarter revenue of $123 million to $129 million, filtering down into operating income of $10.1 million to $13.3 million. Per-share headline earnings should come in at $0.13 to $0.18. Both ranges compare favorably to 2021's third quarter, in which the company earned $118 million on the top line, and posted only $0.02 per share in net income. 10 stocks we like better than Core LaboratoriesWhen our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Core Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of July 27, 2022 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Core Laboratories. The Motley Fool has a disclosure policy.Source